Clinical Validation of the CancerenD24 Screening Test as an Aid for Early Cancer Diagnosis in Healthy Adults Attending the Integrated Cancer Prevention Center

What this Trial Is About

Researchers are evaluating the CancerenD24 index, an algorithm based on the levels of proteins CD24 and CD11b combined with clinical and laboratory data, to help detect cancer early in healthy adults. This observational study aims to assist doctors in diagnosing various cancers at an earlier stage by using this new blood-based screening tool. The study will recruit 2000 healthy male and female subjects over 40 years old without active cancer in the last five years. Participants will provide a venous blood sample during their visit to the medical center, which will be analyzed with the CancerenD24 assay. The test is designed for routine use and is not affected by fasting or the time of day when the blood is drawn. There is no treatment involved in this study, only blood collection and data gathering. The recruitment period will last 36 months. During the study, participants will complete medical exams and questionnaires covering cancer history and other health information. The main outcome measured is the performance of the CancerenD24 assay over three years, including its sensitivity, specificity, and accuracy in detecting cancer. Researchers will also monitor the time to cancer diagnosis up to three years. Participants’ usual medical care continues alongside the study involvement.

CancerenD24 Screening as an Aid to the Clinician for the Diagnosis of Cancer